Qube Research & Technologies (QRT)
BMRN icon

Qube Research & Technologies (QRT)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,100
Closed -$1.06M – 3844
2024
Q1 		$1.06M Buy
+12,100
New +$1.08M ﹤0.01% 2118

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Qube Research & Technologies (QRT)'s BMRN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its BioMarin Pharmaceuticals (BMRN) stake by 3% in Q2 2026, selling an estimated $1.14M and leaving 668,835 shares worth $38.3M. The position accounts for 0.04% of the portfolio, ranked #594.

Qube Research & Technologies (QRT) first reported a position in BMRN in Q3 2018 and has held it in 23 quarters since. The position peaked at $85.4M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Qube Research & Technologies (QRT) held 668,835 shares of BioMarin Pharmaceuticals worth $38.3M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 20,886 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.14M.
  • BioMarin Pharmaceuticals made up 0.04% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #594 holding.
  • Qube Research & Technologies (QRT) first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • Qube Research & Technologies (QRT)'s BioMarin Pharmaceuticals position peaked at $85.4M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.